{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:10:16Z","timestamp":1782738616944,"version":"3.54.5"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to investigate the correlation between nilotinib plasma concentrations and clinical efficacy and safety in patients with chronic myeloid leukemia (CML), thereby supporting personalized therapeutic optimization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective cohort study of 121 CML patients receiving nilotinib with therapeutic drug monitoring (TDM) at Nanfang Hospital of Southern Medical University between March 2021 and February 2024. Major molecular response (MMR) and adverse events (CTCAE v5.0) were analyzed against concentrations. Receiver operating characteristic (ROC) curves defined thresholds; dose-normalized exposure (C\n                      <jats:sub>norm<\/jats:sub>\n                      = C\n                      <jats:sub>min<\/jats:sub>\n                      \/(Dose\/600\u00a0mg)) addressed TDM bias.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The effective group showed higher nilotinib concentrations than those in the ineffective group (1,036.40 \u00b1 463.67 vs. 737.14 \u00b1 518.97\u00a0ng\u00a0mL\n                      <jats:sup>-1<\/jats:sup>\n                      ; P &amp;lt; 0.001), confirmed post-normalization (1,045.10 \u00b1 468.08 vs. 858.34 \u00b1 723.66\u00a0ng\u00a0mL\n                      <jats:sup>-1<\/jats:sup>\n                      ; P &amp;lt; 0.05). The ROC-derived efficacy threshold was 636.99\u00a0ng\u00a0mL\n                      <jats:sup>-1<\/jats:sup>\n                      (AUC = 0.693, 95% CI: 0.596\u20130.791), which was identical after normalization (AUC = 0.655, 95% CI: 0.554\u20130.755). Although adverse events were common (76.9% of patients), they showed no overall concentration dependence (P = 0.288). However, hyperbilirubinemia risk was significantly elevated in patients with concentrations &amp;gt;1,273.98\u00a0ng\u00a0mL\n                      <jats:sup>-1<\/jats:sup>\n                      cohort (50.0% vs. 20.0%\u201322.6%; P = 0.030), with a toxicity threshold identified at 1,290.34\u00a0ng\u00a0mL\n                      <jats:sup>-1<\/jats:sup>\n                      (AUC = 0.656, 95% CI: 0.540\u20130.771). Longer treatment duration was also associated with higher drug exposure (P = 0.029).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Nilotinib concentrations predict MMR attainment independent of TDM-driven dose adjustments (validated via C\n                      <jats:sub>norm<\/jats:sub>\n                      ). We recommend targeting early-phase concentrations &amp;gt;636.99\u00a0ng\u00a0mL\n                      <jats:sup>-1<\/jats:sup>\n                      , monitoring bilirubin above 1,290.34\u00a0ng\u00a0mL\n                      <jats:sup>-1<\/jats:sup>\n                      , and integrating dynamic TDM with pharmacogenetic profiling.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1676800","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T06:08:35Z","timestamp":1757052515000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Correlation analysis between plasma concentration of nilotinib and clinical efficacy and safety in patients with chronic myeloid leukemia: a single\u2013center retrospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Ying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"144","DOI":"10.5045\/br.2022.2021137","article-title":"Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea","volume":"57","author":"Ahn","year":"2022","journal-title":"Blood Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1097\/MS9.0000000000003069","article-title":"A new chapter in CML treatment: the promise of asciminib","volume":"87","author":"Akhtar","year":"2025","journal-title":"Ann. Med. Surg. (Lond)."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.3390\/biomedicines11092478","article-title":"Pharmacokinetics of four tyrosine kinase inhibitors in adult and paediatric chronic myeloid leukaemia patients","volume":"11","author":"Allegra","year":"2023","journal-title":"Biomedicines"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1182\/blood-2018-99-118149","article-title":"Effects of food on the pharmacokinetics of nilotinib in chronic myeloid leukemia: enabling significant dose reduction and relief of treatment burden: the NIFOStudy","volume":"132","author":"Boons","year":"2018","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1586\/17474086.2015.1041910","article-title":"Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events","volume":"8","author":"Carneiro","year":"2015","journal-title":"Expert Rev. Hematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.5045\/br.2023.2023017","article-title":"Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase","volume":"58","author":"Choi","year":"2023","journal-title":"Blood Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2147\/DDDT.S236701","article-title":"Contribution of trough concentration data in the evaluation of multiple-dose pharmacokinetics for drugs with delayed distributional equilibrium and long half-life","volume":"14","author":"Choi","year":"2020","journal-title":"DDDT"},{"key":"B9","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41375-024-02162-5","article-title":"Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in waldenstr\u0151m macroglobulinaemia","volume":"38","author":"de Tute","year":"2024","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"18","author":"Deininger","year":"2020","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ctrv.2009.08.004","article-title":"Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors","volume":"48","author":"Ding","year":"2013","journal-title":"Yao Xue Xue Bao"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3390\/life14091142","article-title":"Cancer patient-derived cell-based models: applications and challenges in functional precision medicine","volume":"14","author":"Dini\u0107","year":"2024","journal-title":"Life (Basel)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr. Engl. Ed."},{"key":"B14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00280-022-04419-1","article-title":"Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy","volume":"89","author":"Fukuda","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1016\/j.clinthera.2019.10.009","article-title":"Utility of therapeutic drug monitoring of imatinib, nilotinib, and dasatinib in chronic myeloid leukemia: a systematic review and meta-analysis","volume":"41","author":"Garcia-Ferrer","year":"2019","journal-title":"Clin. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Front. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"685106","DOI":"10.3389\/fcell.2021.685106","article-title":"Opportunities and challenges of small molecule induced targeted protein degradation","volume":"9","author":"He","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1182\/blood-2023-182765","article-title":"TKI dose optimization based on therapeutic drug Monitoring(TDM) with encouraging outcomes and well-tolerated for chronic myeloid leukaemia patients","volume":"142","author":"He","year":"2023","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1016\/j.xphs.2019.01.028","article-title":"Physiologically based pharmacokinetic modeling to supplement nilotinib pharmacokinetics and confirm dose selection in pediatric patients","volume":"108","author":"Heimbach","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/1078-0432.CCR-19-0090","article-title":"Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic Myeloid leukemia or acute lymphoblastic leukemia","volume":"26","author":"Hijiya","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1002\/sim.4323","article-title":"Bayesian information criterion for longitudinal and clustered data","volume":"30","author":"Jones","year":"2011","journal-title":"Statistics Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J. Intern Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00228-011-1200-7","article-title":"Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed ph+ chronic myeloid leukemia in chronic phase","volume":"68","author":"Larson","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.2217\/fon-2022-1008","article-title":"Rash with different types of BCR-ABL inhibitors in chronic myelogenous leukemia: a systematic review and meta-analysis","volume":"19","author":"Li","year":"2023","journal-title":"Future Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1248\/bpb.b15-00103","article-title":"Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia","volume":"38","author":"Miura","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"B26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","article-title":"Therapeutic drug monitoring of oral targeted antineoplastic drugs","volume":"77","author":"Mueller-Schoell","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5306\/wjco.v12.i2.69","article-title":"Chronic myeloid leukemia-from the philadelphia chromosome to specific target drugs: a literature review","volume":"12","author":"Sampaio","year":"2021","journal-title":"World J. Clin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1038\/sj.leu.2404827","article-title":"UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia","volume":"21","author":"Singer","year":"2007","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2012.09.004","article-title":"Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis","volume":"39","author":"Teo","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1002\/jcph.1312","article-title":"Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor","volume":"58","author":"Tian","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.3390\/molecules25174026","article-title":"Review of chromatographic methods coupled with modern detection techniques applied in the therapeutic drugs monitoring (TDM)","volume":"25","author":"Tuzimski","year":"2020","journal-title":"Molecules"},{"key":"B34","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.7534\/j.issn.1009-2137.2018.01.019","article-title":"Correlation of serum concentration of nilotinib with clinical efficacy in patients with chronic myeloid leukemia","volume":"26","author":"Wang","year":"2018","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B36","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/cpt.1963","article-title":"Opportunities for quantitative translational modelling in oncology","volume":"108","author":"Yates","year":"2020","journal-title":"Clin. Pharmacol. Ther."}],"updated-by":[{"DOI":"10.3389\/fphar.2025.1699696","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000}},{"DOI":"10.3389\/fphar.2025.1730637","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1676800\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:08:41Z","timestamp":1765368521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1676800\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":36,"alternative-id":["10.3389\/fphar.2025.1676800"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1676800","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"article-number":"1676800"}}